Business Wire

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza

Del

BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of influenza (flu).

Under the terms of the agreement, BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study.

BioNTech will receive $120 million in upfront, equity and near-term research payments and up to an additional $305 million in potential development, regulatory and commercial milestone payments. In addition, BioNTech will receive up to double-digit tiered royalty payments associated with worldwide sales if the program reaches commercialization.

BioNTech is an industry leader in mRNA vaccine approaches with validated science, innovative manufacturing expertise and a broad understanding of the clinical applications of this technology.

“Today’s agreement with Pfizer is one of a number of steps that we are taking to rapidly build a sustainable R&D presence in infectious disease, combining our deep understanding of the immune system to treat disease with the cutting-edge technologies and significant infrastructure that we have built-up over many years to develop immunotherapy treatments,” said Prof. Dr. Ugur Sahin, Co-Founder and CEO of BioNTech. “A significant presence in infectious disease supports our goal of building a global immunotherapy company that provides more effective and precise immune-mediated approaches for the prevention and treatment of serious illnesses, such as the prevention of flu and the treatment of cancer.”

Kathrin Jansen, Senior Vice President and Head of Pfizer’s Vaccine Research and Development Unit said, “Innovative vaccine approaches are urgently needed to provide improved protection against seasonal flu, and to respond rapidly and in quantity to pandemic influenza threats. mRNA vaccines offer a novel approach to code for any protein or multiple proteins, and the potential to manufacture higher potency flu vaccines more rapidly and at a lower cost than contemporary flu vaccines. BioNTech is one of the industry leaders in mRNA technology and we are looking forward to working closely with them to help bring cutting-edge mRNA influenza vaccines to the market to improve people’s lives.”

About BioNTech

BioNTech is Europe’s largest privately-held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The Company combines all building blocks for individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators and small molecules. BioNTech’s commercial approach is validated by five top-tier corporate partnerships with Genentech, Genmab, Eli Lilly, Sanofi and Bayer Animal Health and its scientific approach through over 60 peer-reviewed scientific publications, including five publications in Nature. Founded in 2008, BioNTech’s financial shareholders include the Struengmann Family Office as its majority shareholder, Fidelity Management & Research Company, Invus, Janus Henderson Investors, MIG Fonds, Redmile Group, Salvia and several European family offices.

For more information, see www.biontech.de.

About Pfizer: Working together for a healthier world ®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

DISCLOSURE NOTICE: The information contained in this release is as of August 16, 2018. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about mRNA-based vaccines for prevention of influenza (flu) and Pfizer’s and BioNTech’s collaboration to develop such vaccines, including their potential benefits that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical study commencement and completion dates as well as the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing data; risks associated with preliminary data; the risk that clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of any potential product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether; whether and when drug applications may be filed in any jurisdictions for any potential indications for Pfizer’s and BioNTech’s potential vaccine candidate for prevention of influenza (flu); whether and when any such applications may be approved by regulatory authorities, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of Pfizer’s and BioNTech’s potential vaccine candidate for prevention of influenza (flu); and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results,” as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at  www.sec.gov  and www.pfizer.com .

Contact information

BioNTech AG
Sean Marett, +49 (0) 6131 9084 1803
Mobile: + 49 (0) 16 09 44 73 173
Chief Business & Commercial Officer
Sean.Marett@biontech.de
or
International Media & Investor Enquiries:
Consilium Strategic Communications
Mary-Jane Elliott / Sukaina Virji, +44 (0) 20 3709 5700
biontech@consilium-comms.com
or
US Investor Enquiries:
Westwicke Partners
John Woolford, + 1 (443) 213 0506
john.woolford@westwicke.com
or
German Media Enquiries:
Trophic Communications
Gretchen Schweitzer / Dr. Stephanie May, +49 (0) 89 23 88 77 30
Mobile: +49 (0) 171 185 56 82
may@trophic.eu

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

PMI: Taking Bold Action for Global Change: a Conversation on Tobacco Today and Transformation for Tomorrow25.9.2018 15:43Pressemelding

During the 2018 Concordia Annual Summit, taking place in September 24 & 25 in New York, André Calantzopoulos, CEO of Philip Morris International, delivered a speech highlighting the need to have a dialogue between the industry, leaders, policy-makers, scientists, medical, and public health professionals in order to provide the 1.1 billion people who smoke with better alternatives to cigarettes. The Concordia Annual Summit, which coincides with the United Nations General Assembly (UNGA) meeting, convenes the world’s most prominent business, government, and nonprofit leaders to foster dialogue and enable effective partnerships for positive social impact. The remarks by André Calantzopoulos follow: “I'm the Chief Executive Officer of a tobacco company. I’m here today because, as global leaders come together in New York for the United Nations General Assembly, this is the time and place to discuss today's problems and their potential solutions. “Smoking tobacco is a behavioral risk factor

ExaGrid Achieves a Net Promoter Score of +7325.9.2018 15:22Pressemelding

ExaGrid ®, a leading provider of hyper-converged secondary storage for backup, today announced that the company has achieved a Net Promoter Score (NPS) of +73 in response to a recently conducted NPS survey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180925005883/en/ The NPS customer loyalty metric measures how likely existing customers are to recommend a vendor’s product or service to a colleague. The resulting NPS score can be as low as -100 or as high as +100. Most of ExaGrid’s competitors have an NPS of between +10 and +20 versus ExaGrid at +73. We attribute the satisfaction of our customers to our unique product architecture, the fact that the product “just works,” and also to a unique support model: Each customer is assigned to a senior level 2 support tech. Customers consistently deal with the same support tech who virtually becomes an extension of the customer’s IT team; the tech knows the customer, their environm

Abu Dhabi International Hunting and Equestrian Exhibition 2018 Opens its Doors Today25.9.2018 15:17Pressemelding

Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler's Representative in Al Dhafra Region, Chairman of the Emirates Falconers’ Club, the 16th Edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) was inaugurated at Abu Dhabi National Exhibition Center (ADNEC), which will run until 29th September, and celebrates this year the centennial of the late Sheikh Zayed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180925005875/en/ Scenes from ADIHEX - (Photo: AETOSWire) The event is organized by the Emirates Falconers’ Club and is supported by the Environment Agency - Abu Dhabi (EAD), International Fund for Houbara Conservation (IFHC), the Department of Culture and Tourism (DCT) and The Cultural Programs and Heritage Festivals Committee in addition to many local, regional and international media partners. The main sponsor is His Highness Sheikh Mansoor bin Zayed Al Nahyan Global A

Andersen Global Welcomes Tufiño & Villegas in Bolivia25.9.2018 13:30Pressemelding

Andersen Global continues its growth in Latin America with news that one of the premier tax law firms in Bolivia, Estudio Jurídico Tufiño Villegas & Asoc., has become a collaborating firm of Andersen Global. Tufiño & Villegas specializes in providing legal services to both local and foreign corporations that do business in Bolivia. With offices in La Paz, Santa Cruz and Cochabamba, the signing of a Collaboration Agreement with Tufiño & Villegas kickstarts Andersen Global’s presence in the South American country. The international organization has almost doubled its headcount in Latin America in the past eight months. Through its member firms and collaborating firms, Andersen Global already has a strong presence in the region in several major economic hubs – Mexico, Guatemala, Panama, Chile, Uruguay, Ecuador, Brazil, and most recently Paraguay. Led by Founders and Managing Partners Alvaro Villegas Aldazosa and Jose Luis Tufiño, the firm, Tufiño & Villegas, was created in 1995 as a tax b

Arensis and Schneider Electric Launch Smart Microgrid Partnership and Development of ENTRADE IO Blockchain Technology25.9.2018 13:00Pressemelding

Arensis, a leading international provider of decentralized energy systems, and Schneider Electric, a leader in microgrid development with integrated efficiency solutions combining energy, automation and software, today announced the joint development of its smart microgrid pilot program. As part of the pilot, Arensis and Schneider Electric will develop a blockchain Application Programming Interface (API) platform for ENTRADE IO, a newly-formed company founded by the CEO of Arensis for off grid project financing and the sale of renewable energy in remote areas around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180925005362/en/ Schneider Electric augmented reality (AR) applications developed for Arensis and ENTRADE IO Smart Microgrid solutions. (Graphic: Business Wire) Joint development of the smart microgrid systems, combining waste-to-energy, solar and storage, will launch in North America with plans for growth

Analogix Introduces Industry’s Lowest Power eDP TCON with In-Cell Touch for Latest Generation Notebooks25.9.2018 13:00Pressemelding

Analogix Semiconductor, Inc. today announced its ANX2403, the industry’s lowest power Full HD embedded DisplayPort™ 1.4 (eDP) timing controller (TCON) with panel self-refresh (PSR), VESA DisplayHDR™ 400 support, and in-cell finger and active stylus touch for notebook PCs with graphics display resolution up to 1920x1280. Leveraging Analogix’s technology leadership in low-power processes, the ANX2403 reduces the Full HD 60Hz power consumption to 60mW using 28nm process technology, a 35% reduction over the 40nm technology and more than 50% reduction over the 55nm technology, becoming the lowest power TCON in the industry. Moreover, the ANX2403 supports Intel low refresh rate (LRR) and PSR2 for even further power reductions. “The ANX2403 brings together our capabilities in low-power processes, in-cell touch, and high-dynamic-range (HDR) technology, offering the lowest power consumption to date, better image performance, and thinner panels with reduced bezels at a lower cost to display pane